Insulet (Germany) Today

GOV Stock  EUR 204.80  1.50  0.74%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Tiny

 
High
 
Low
Insulet is trading at 204.80 as of the 15th of February 2026. This is a 0.74% increase since the beginning of the trading day. The stock's lowest day price was 201.5. Insulet has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of November 2025 and ending today, the 15th of February 2026. Click here to learn more.
Business Domain
Health Care Equipment & Services
Category
Healthcare
Classification
Health Care
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. INSULET CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. The company has 70.35 M outstanding shares. More on Insulet

Moving together with Insulet Stock

  0.83BYRA BANK RAKYAT INDPairCorr

Moving against Insulet Stock

  0.85ASME ASML Holding NVPairCorr
  0.84TQI TELECOM ITALIAPairCorr
  0.81FPP0 ALTYNGOLD PLC LSPairCorr
  0.8FV6 EMMI NPairCorr
  0.78HKT HK Electric InvestmentsPairCorr
  0.76BSI BE Semiconductor Ind Earnings Call This WeekPairCorr

Insulet Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Insulet's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Insulet or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEOAshley McEvoy
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Insulet's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Insulet's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Insulet utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Insulet's leverage profile, showing how much of Insulet's resources are funded through borrowing.
Liquidity
Insulet cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Insulet has accumulated 96 M in total debt with debt to equity ratio (D/E) of 272.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Insulet has a current ratio of 4.27, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Insulet until it has trouble settling it off, either with new capital or with free cash flow. So, Insulet's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Insulet sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Insulet to invest in growth at high rates of return. When we think about Insulet's use of debt, we should always consider it together with cash and equity.

Investments

(14.73 Million)
Insulet (GOV) is traded on Frankfurt Exchange in Germany and employs 3,900 people. Insulet is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 14.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Insulet's market, we take the total number of its shares issued and multiply it by Insulet's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Insulet classifies itself under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 70.35 M outstanding shares. Insulet has accumulated about 316.37 M in cash with 430.3 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.3.
Check Insulet Probability Of Bankruptcy
Ownership Allocation
Insulet has a total of 70.35 Million outstanding shares. The majority of Insulet outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Insulet to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Insulet. Please pay attention to any change in the institutional holdings of Insulet as this could imply that something significant has changed or is about to change at the company. Also note that almost four thousand two hundred twenty-one invesors are currently shorting Insulet expressing very little confidence in its future performance.
Check Insulet Ownership Details

Insulet Historical Income Statement

At this time, Insulet's Gross Profit is most likely to increase significantly in the upcoming years. The Insulet's current Operating Income is estimated to increase to about 373 M, while Interest Expense is projected to decrease to roughly 27 M. View More Fundamentals

Insulet Stock Against Markets

Insulet Stock Analysis Notes

About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.85. Insulet had not issued any dividends in recent years. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. INSULET CORP operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1169 people. To learn more about Insulet call Ashley McEvoy at 978 600 7000 or check out https://www.insulet.com.

Insulet Quarterly Total Revenue

706.3 Million

Insulet Investment Alerts

Insulet generated a negative expected return over the last 90 days
Insulet is unlikely to experience financial distress in the next 2 years
Insulet has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
Over 100.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Exploring Analyst Estimates for Insulet Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Singapore

Insulet Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 14.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Insulet's market, we take the total number of its shares issued and multiply it by Insulet's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Insulet Profitablity

Insulet's profitability indicators refer to fundamental financial ratios that showcase Insulet's ability to generate income relative to its revenue or operating costs. If, let's say, Insulet is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Insulet's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Insulet's profitability requires more research than a typical breakdown of Insulet's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17.

Management Efficiency

Insulet has return on total asset (ROA) of 0.0874 % which means that it generated a profit of $0.0874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1968 %, meaning that it generated $0.1968 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Insulet's Other Current Assets are most likely to increase significantly in the upcoming years. The Insulet's current Total Current Assets is estimated to increase to about 2.3 B, while Net Tangible Assets are projected to decrease to roughly 209.1 M.
Leadership effectiveness at Insulet is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Operating Margin
0.1666
Profit Margin
0.0976
Beta
1.418
Return On Assets
0.0874
Return On Equity
0.1968

Technical Drivers

As of the 15th of February 2026, Insulet retains the Market Risk Adjusted Performance of (9.16), standard deviation of 2.39, and Risk Adjusted Performance of (0.13). Insulet technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Insulet coefficient of variation, treynor ratio, skewness, as well as the relationship between the variance and value at risk to decide if Insulet is priced fairly, providing market reflects its last-minute price of 204.8 per share.

Insulet Price Movement Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. Insulet Tanh Of Price Series is a hyperbolic price transformation function.

Insulet Outstanding Bonds

Insulet issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Insulet uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Insulet bonds can be classified according to their maturity, which is the date when Insulet has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Insulet Predictive Daily Indicators

Insulet intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Insulet stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Insulet Forecast Models

Insulet's time-series forecasting models are one of many Insulet's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Insulet's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Insulet without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Insulet Corporate Management

Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
Philip HildaleSenior CareProfile
Clare TrachtmanVice RelationsProfile
Andrew IsaacsonSenior DevelopmentProfile
John JDSenior CounselProfile
When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Insulet Stock please use our How to Invest in Insulet guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Insulet's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.